Climb Bio Stock (NASDAQ:CLYM)

Financials Chart

Previous Close

$1.23

52W Range

$1.05 - $11.55

50D Avg

$1.32

200D Avg

$3.76

Market Cap

$85.02M

Avg Vol (3M)

$242.78K

Beta

-0.10

Div Yield

-

CLYM Company Profile

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

17

IPO Date

-

Website

CLYM Performance

CLYM Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-82.02M	$-40.27M	$-45.13M
Net Income	$-73.90M	$-35.12M	$-45.24M
EBITDA	$-30.36M	$-40.27M	$-45.13M
Basic EPS	-	$-1.30	$-1.72
Diluted EPS	-	$-1.30	$-1.72

Fiscal year ends in Dec 24 | Currency in USD